EDTUTC-4 New YorkLog in Sign up

RARE
Ultragenyx Pharmaceutical Inc.
stockNASDAQ

At CloseOct 2, 2026 3:59:58 PM EDT

15.21USD+3.119%(+0.46)3,880,768

Pre-marketOct 2, 2026 9:26:30 AM EDT

14.80USD+0.339%(+0.05)

After-hoursOct 2, 2026 4:27:30 PM EDT

15.33USD+0.789%(+0.12)

RARE News

Day breaks

02:00 AM EDTUltragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) ·

GlobeNewswire Inc.

10:00 AM EDTINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE ·

PR Newswire

05:34 PM EDTINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE ·

PR Newswire

02:49 AM EDTCan Fayuvi FDA approval lift RARE stock further? ·

The Economic Times

02:18 AM EDTUltragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript ·

Seeking Alpha

03:48 PM EDTUltragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) ·

GlobeNewswire Inc.

03:39 PM EDTUltragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome ·

Seeking Alpha

11:30 AM EDTWhy Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? ·

Zacks Investment Research

08:00 AM EDTAmlogenyx to Present at the Wells Fargo 21ˢᵗ Annual Healthcare Conference ·

GlobeNewswire Inc.

02:12 PM EDTThis week’s top stock pitches from investment newsletters. ·

Stock Analysis Compilation

04:04 AM EDTFabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy ·

GlobeNewswire Inc.